TrialHead & neck2016

Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.

Robert H I Andtbacka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.